JP2019518775A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518775A5
JP2019518775A5 JP2018567237A JP2018567237A JP2019518775A5 JP 2019518775 A5 JP2019518775 A5 JP 2019518775A5 JP 2018567237 A JP2018567237 A JP 2018567237A JP 2018567237 A JP2018567237 A JP 2018567237A JP 2019518775 A5 JP2019518775 A5 JP 2019518775A5
Authority
JP
Japan
Prior art keywords
cells
ipscs
wild
progenitor cells
aspa gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518775A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038853 external-priority patent/WO2017223373A1/en
Publication of JP2019518775A publication Critical patent/JP2019518775A/ja
Publication of JP2019518775A5 publication Critical patent/JP2019518775A5/ja
Priority to JP2022199966A priority Critical patent/JP2023029376A/ja
Pending legal-status Critical Current

Links

JP2018567237A 2016-06-22 2017-06-22 カナバン病の治療 Pending JP2019518775A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022199966A JP2023029376A (ja) 2016-06-22 2022-12-15 カナバン病の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353515P 2016-06-22 2016-06-22
US62/353,515 2016-06-22
PCT/US2017/038853 WO2017223373A1 (en) 2016-06-22 2017-06-22 Treatment of canavan disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022199966A Division JP2023029376A (ja) 2016-06-22 2022-12-15 カナバン病の治療

Publications (2)

Publication Number Publication Date
JP2019518775A JP2019518775A (ja) 2019-07-04
JP2019518775A5 true JP2019518775A5 (https=) 2020-07-27

Family

ID=60784859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567237A Pending JP2019518775A (ja) 2016-06-22 2017-06-22 カナバン病の治療
JP2022199966A Pending JP2023029376A (ja) 2016-06-22 2022-12-15 カナバン病の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022199966A Pending JP2023029376A (ja) 2016-06-22 2022-12-15 カナバン病の治療

Country Status (7)

Country Link
US (2) US20190307808A1 (https=)
EP (1) EP3474876A4 (https=)
JP (2) JP2019518775A (https=)
CN (1) CN110035764B (https=)
AU (1) AU2017281374A1 (https=)
CA (1) CA3028714A1 (https=)
WO (1) WO2017223373A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076206A1 (en) * 2020-10-05 2022-04-14 City Of Hope Treatment of canavan disease
CN117999363A (zh) * 2021-08-17 2024-05-07 希望之城 用于无细胞的dna表观遗传的胃肠道癌检测以及治疗的组成物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172963C (en) * 1993-09-29 2007-09-11 Reuben Matalon Aspartoacylase gene, protein, and methods of screening for mutations associated with canavan disease
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
PL2861733T3 (pl) * 2012-05-30 2021-04-19 Rowan University Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego
JP6541577B2 (ja) * 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
WO2015153760A2 (en) * 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
WO2015188056A1 (en) * 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design

Similar Documents

Publication Publication Date Title
Jopling et al. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration
Wang et al. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice
Seki et al. Methods of induced pluripotent stem cells for clinical application
WO2010108005A3 (en) Novel neural progenitors from pluripotent stem cells, methods of producing same and use to produce neural cells
JP2017035113A5 (https=)
Martins et al. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine
Iglesias-García et al. Induced pluripotent stem cells as a new strategy for cardiac regeneration and disease modeling
JP2015165810A5 (https=)
Knapp et al. Regeneration and reprogramming
RU2012101874A (ru) Получение индуцированных плюрипотентных стволовых клеток из пуповинной крови
CN103562376A (zh) 复壮细胞的方法
CN105039399A (zh) 多能干细胞-遗传性心肌病心肌细胞及其制备方法
CN103740757B (zh) 一种利用重编程制备猪神经干细胞的方法
KR102849512B1 (ko) 성체 줄기 세포로부터의 유도된 심장박동기 및 푸르키네 세포
Xie et al. The application of human iPSCs in neurological diseases: from bench to bedside
JP2019518775A5 (https=)
Hartfield et al. Cellular reprogramming: a new approach to modelling Parkinson's disease
Fujiwara et al. Cellular and molecular mechanisms of the restoration of human APP transgenic mouse cognitive dysfunction after transplant of human iPS cell-derived neural cells
WO2012075462A3 (en) Methods and compositions for treatment of muscular dystrophy
RU2011153283A (ru) Получение генетически скорректированных, здоровых индуцированных плюрипотентных стволовых клеток
Han et al. Stem cell therapy for Parkinson’s disease
Maherali et al. Induced pluripotency of mouse and human somatic cells
Friedrichs et al. Modeling long QT syndromes using induced pluripotent stem cells: current progress and future challenges
Young et al. Patient-specific induced pluripotent stem cells as a platform for disease modeling
Jang et al. Induced pluripotent stem cells for modeling of pediatric neurological disorders